Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,140 shares of the biopharmaceutical company’s stock after selling 2,295 shares during the period. Envestnet Asset Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $6,109,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of ALNY. Allspring Global Investments Holdings LLC boosted its stake in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth about $26,000. Altitude Crest Partners Inc. acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $30,000. V Square Quantitative Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $52,000. Finally, Prestige Wealth Management Group LLC grew its position in shares of Alnylam Pharmaceuticals by 69.8% in the first quarter. Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 194 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.1 %

Shares of ALNY opened at $274.91 on Monday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $287.55. The stock has a market cap of $34.77 billion, a price-to-earnings ratio of -102.58 and a beta of 0.38. The business has a 50-day simple moving average of $263.00 and a two-hundred day simple moving average of $203.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same quarter in the previous year, the business earned ($2.21) EPS. The company’s quarterly revenue was up 107.0% on a year-over-year basis. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ALNY. Leerink Partners increased their price target on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a research note on Tuesday, June 25th. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, August 30th. Stifel Nicolaus lifted their price target on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. TD Cowen lifted their price target on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 19th. Seven equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $279.14.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now directly owns 136 shares of the company’s stock, valued at $35,632. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,491 shares of company stock valued at $15,446,733. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.